Leveraging intratumoral probiotics for pancreatic cancer immunotherapy via xenophagy - PubMed
5 days ago
- #probiotic-mediated immunotherapy
- #pancreatic cancer
- #xenophagy
- Intratumoral probiotics, specifically Bifidobacterium longum (B. longum), can colonize pancreatic ductal adenocarcinoma (PDAC) tumors and invade PDAC cells.
- The anti-tumor effects of B. longum are driven by rapamycin-induced xenophagy, a process termed XenoPro.
- XenoPro suppresses tumor growth by presenting B. longum-derived neoantigens, activating CD4+ T cells, and inducing tumor-specific cytotoxicity.
- A vaccine containing the top 12 immunogenic neoantigens from 40 predicted showed potent anti-tumor effects in PDAC, colorectal cancer, and melanoma models.
- XenoPro enhances immune cell infiltration and improves the efficacy of immune checkpoint inhibitors (ICIs), offering a promising strategy for PDAC immunotherapy.